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Abstract: G protein-coupled receptors (GPCRs), major targets of drug discovery, are 
organized in dimeric and/or oligomeric clusters. The minimal oligomeric unit, the dimer, is 
composed of two protomers, which can behave differently within the dimer. Several 
examples of GPCR asymmetry within dimers at the level of ligand binding, ligand-
promoted conformational changes, conformational changes within transmembrane 
domains, G protein coupling, and most recently GPCR-interacting proteins (GIPs), have 
been reported in the literature. Asymmetric organization of GPCR dimers has important 
implications on GPCR function and drug design. Indeed, the extension of the “asymmetry 
concept” to GIPs adds a new level of specific therapeutic intervention. 
Keywords: GPCR; dimerization; GIP; allosterism 
 
1. Introduction 
A growing body of pharmacological, biochemical and biophysical data indicate that GPCRs form 
functional homo- and hetero-dimers and most likely higher-order oligomers [1,2]. Formation of such 
oligomeric structures has been shown to provide shielding from the quality-control checkpoints during 
the biosynthetic pathway [3] and to have an important role in modulating GPCR function and signaling [4]. 
In addition, this oligomeric organization raises a fundamental question: does each protomer within a 
GPCR oligomer operate as an independent functional unit or do the different protomers 
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intercommunicate to insure the signaling response of the cell? Communication within dimers has 
indeed been observed for several GPCRs at different levels. Ligand binding to one protomer has been 
shown to modify the properties of the ligand binding pocket of the second protomer. The latter 
observation most likely involves ligand-induced conformational changes that are transmitted from one 
protomer to the other. Intercommunication among the different protomers results in dimer asymmetry 
and asymmetric recruitment of GPCR-interacting proteins (GIPs) including heterotrimeric G proteins. 
This mini-review summarizes the evidence supporting the emerging concept of asymmetric behavior 
within a GPCR complex. We will briefly discuss asymmetry in G protein coupling, ligand binding, 
conformational changes within transmembrane domains, and binding of GIPs. 
2. Asymmetry at the Level of G Protein Binding 
Reconstitution of purified monomeric GPCRs, in high-density lipoprotein phospholipid bilayer 
particles, showed that monomeric GPCRs are able to couple to G proteins. These and similar results 
clearly demonstrate that the minimal functional unit consists of 1 receptor monomer activating its 
cognate G protein (Figure 1a) [5-7]. When rod outer segment membranes were solubilized with 
different detergents to obtain preparations enriched in monomeric, dimeric and oligomeric rhodopsin 
structures, monomeric rhodopsin was indeed able to activate its G protein, the heterotrimeric 
transducin (Gt) confirming studies in reconstituted systems [8]. However, preparations containing 
mostly dimeric and oligomeric rhodopsin appeared to be more active.  
Figure 1. Stoichiometry of G protein coupling to GPCR dimers. (a) The minimal 
functional unit is constituted of one monomeric receptor and one heterotrimeric G protein; 
(b) Two G proteins binding, each, one protomer within a dimer; (c) Asymmetric G protein 
coupling to a receptor dimer: only one G protein binds one protomer of the dimer. 
 
By extrapolating the idea that a GPCR monomer couples to a single G protein, one might anticipate 
that GPCR dimers, composed of two protomers, bind to two G proteins (Figure 1b). Nevertheless, to 
our knowledge, there is no clear experimental evidence today confirming such an arrangement, except 
one study published in 2008 by Parker et al. on the neuropeptide Y (NPY) Y2 receptor. Using 
radiolabeled-ligand binding assays, GTPγS binding and gradient ultracentrifugation experiments, the 
authors show that Y2 receptors and G proteins could be solubilized in complexes of 2:2, 2:1 and 1:1 
stoichiometry, depending on the detergent and the concentration of agonist used [9]. Cumulative 
evidence from the literature is, however, rather consistent with a 2:1 stoichiometry with two receptor 
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protomers coupling only one heterotrimeric G protein (Figure 1c). Such a stoichiometry implies that 
GPCR dimers have a radically different mode of function than monomers therefore introducing the 
concept of asymmetry. 
GPCR asymmetry was intensely debated when the first high-resolution structure of rhodopsin, the 
archetypal class A GPCR, was solved by Palczewski and associates [10]. Computational docking 
simulations and molecular modeling of rhodopsin and its Gt protein illustrated that the receptor-facing 
surface of Gt is too large with respect to the rhodopsin cytoplasmic surface. These results suggest that 
GPCR dimer formation is a pre-requisite to fully accommodate the binding of the G protein [11,12]. 
Concomitantly, a 2:1 stoichiometry was proposed for another class A GPCR, the leukotriene B4 
receptors BLT1 and its cognate G protein, by using purified proteins and chemical cross-linking [13]. 
These pioneering studies raised the fundamental question of the respective role of each protomer 
within a dimer in regards to G protein activation. Indeed, there are at least two ways for the G protein 
to contact the dimer (through protomer 1 or 2). Based on this assumption, asymmetry of the receptor 
dimer might be dictated by the position of the Gα subunit relative to the agonist-occupied monomer. A 
possible model would be that activation of one of the protomers favors an oriented interaction of the 
receptor dimer with the G protein in such a way that the agonist-occupied protomer directly interacts 
with the G protein and is therefore stabilized in a fully active, high affinity conformation, whereas the 
other protomer remains in an uncoupled, low affinity conformation [14]. Further important progress on 
how the receptor dimer interacts with the G protein has been made using BLT1 and dopamine D2 
homodimers as models. By using the intrinsic fluorescence properties of the BLT1 receptor to monitor 
its activation, Damian et al. showed that a receptor dimer with only a single agonist-occupied subunit 
can trigger G protein activation. Interestingly, the two subunits of the dimer in the G protein-coupled 
state differ in their conformation, even when both protomers are occupied by agonists. In the absence 
of G protein coupling, no such asymmetric conformational changes were observed [15]. These results 
suggest that the interaction of the G protein with the receptor dimer would bring specific constraints, 
which prevent a symmetric functioning of the dimer and that the G protein itself might be partly 
responsible for the asymmetric functioning in a context where ligand binding cis-activates G protein 
binding to the same protomer [14]. On the other hand, using an original approach based on a functional 
complementation assay with the D2 receptor, allosteric communication between protomers of GPCR 
dimers was proposed [16]. This study confirmed that agonist binding to a single protomer within the 
dimer can maximally activate the G protein. Moreover, activation of the second protomer inhibits the 
functional response whereas inverse agonist binding enhances signaling, definitely proving that the way 
the two protomers contribute to the activated complex with the G protein is not symmetric, and that 
activation requires different conformational changes in each protomer [16]. Such asymmetry also applies 
to class C GPCRs as exemplified by the GABAB receptor, which is an obligatory heteromer composed of 
GB1 and GB2 subunits, with GB1 binding the ligand and GB2 activating the G protein [17,18]. 
Collectively, the most convincing examples in the literature favor a 2:1 stoichiometry between the 
receptor and the G protein. Several studies using purified and reconstituted GPCRs suggest a 1:1 
stoichiometry. However, one should be careful when extrapolating these in vitro observations into a 
more physiological context; i.e. the plasma membrane of mammalian cells. Asymmetric behavior of 
GPCR dimers is further supported by observations at the level of ligand binding and ligand-promoted 
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conformational changes within the heptahelical transmembrane domain as discussed in the next 
paragraphs. 
3. Asymmetry at the Level of Ligand Binding 
The phenomenon of allostery has been observed in many biological processes, and refers to 
different, albeit related, mechanisms by which protein function can be regulated and fine-tuned in 
either a positive or negative direction [19]. In pharmacology, allosteric modulation of a receptor results 
from the binding of allosteric molecules at a different site (allosteric site) from that of the endogenous 
ligand (orthosteric site). Allosteric modulators normally induce a conformational change in the 
receptor resulting in a positive or negative effect on binding affinity and efficacy of ligand binding to 
the orthosteric site. In the context of GPCR oligomerization, each protomer in the complex possesses 
an orthosteric binding pocket and one can expect that the orthosteric site of one protomer could exert 
allosteric effects on the orthosteric site of another protomer [20]. 
Allosteric interactions between ligand binding sites within a dimeric complex result in either 
positive or negative cooperativity. This fact raises the question of stoichiometry concerning the 
number of ligand molecules binding a dimer. The majority of the examples in the literature suggest 
that negative cooperativity is due to a single ligand molecule binding one protomer of the dimer, 
whereas positive cooperativity results from two ligand molecules binding, each, one protomer in a 
dimer. However, exceptions from this rule exist as mentioned below. 
Positive cooperativity has early on been reported for several GPCRs. In the case of agonist binding 
to the µ/δ opioid receptor (OR) heteromer, both agonists are required for efficient MAP kinase 
activation (Figures 2a,b) [21]. Similarly, activation of both protomers of a muscarinic M3 homomer is 
required for beta-arrestin recruitment [22]. Positive cooperative binding was also documented for class 
C GPCRs. Binding of a single agonist is sufficient for the activation of the homomeric metabotropic 
glutamate receptor (mGluR) 5. However, full activation requires binding of two agonist molecules and 
the closure of both agonist-binding domains of the homodimer, also called venus fly trap (VFT) [23]. 
Another type of positive allosterism is seen in the CXCR2/δOR heteromer, where CXCR2 antagonists 
enhance the function of both peptide and alkaloid-based agonists at the δOR when the two receptors 
are co-expressed [24]. 
Negative binding cooperativity of allosteric nature has been observed in other cases such as homo- 
and heteromers of glycoprotein hormone receptors. Ligand binding to the large extracellular 
ectodomain triggers activation of constitutive receptor dimers that are mainly stabilized by interactions 
between the transmembrane domains. Using competition, saturation and dissociation kinetics binding 
experiments, Urizar et al. showed for the first time for class A GPCRs that the two orthosteric sites of 
each dimer are implicated in negative allosteric interactions with one another (Figure 2c) [25]. 
Similarly, an extensive pharmacological characterization of the dopamine D2 receptor by performing 
saturation binding assays and dissociation kinetics with three different radioligands showed that some 
D2 receptor antagonists exhibit negative binding cooperativity within a D2 homodimer [26]. 
Furthermore, chemokine receptor heteromers display allosteric modulation in ligand binding and 
dissociation kinetic experiments strongly suggesting negative cooperativity for several different 
heteromers. Trans-inhibition of ligand binding was observed between CCR5 and CCR2b co-expressed 
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in the same cell line and in cells endogenously expressing both receptors [27,28]. CCR5-specific 
ligands, unable to compete for the binding of CCR2-specific ligands on cells expressing CCR2 alone, 
inhibited this binding when both receptors were co-expressed. Similar results were obtained with 
CCR2-selective ligands. 
Figure 2. Asymmetry in ligand binding within a GPCR dimer. Positive cooperativity: (a) 
One agonist (A) binding to a dimer results in GPCR partial activation; but (b) two agonists 
(A, B) are required for full activation. Ligand B can be identical to agonist A or a different 
agonist or an antagonist, which can enhance GPCR activation. Negative cooperativity; 
(c) Agonist A binding to protomer 1 inhibits the binding of ligand B to protomer 2, 
therefore suppressing protomer 2-dependent signaling; or (d) agonist A binding to 
protomer 1 inhibits ligand B-induced protomer 2 signaling. 
 
Moreover, in the context of the µOR/α2A-adrenoceptor (AR) heteromer, Vilardaga et al. showed 
that simultaneous binding of the two respective agonists, norepinephrine and morphine, inhibits α2A-
AR-dependent Gi signaling and the downstream MAP kinase cascade [29]. These results interestingly 
show that negative cooperativity may occur in a dimer where both binding pockets are occupied by 
their respective agonists (Figure 2d). 
Recently, Albizu et al. used fluorescent-labeled ligands to study oxytocine receptor dimerization in 
native tissues. A mixture of two antagonists, either labeled with an energy donor or acceptor, generated 
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a strong FRET signal. However, only marginal FRET signals were obtained when two labeled agonists 
were used indicating that agonist binding to one protomer suppresses agonist binding to the second 
protomer whereas no such inhibitory effect is seen for antagonist binding [30]. Both positive and 
negative cooperativity have also been reported within the same heteromer as illustrated by the 
dopamine D2 receptor and somatostatin sst5 receptor heteromer, for which the positive cooperativity 
was observed for D2 agonists and negative cooperativity for D2 antagonists [31]. 
Collectively, different types of negative and positive allosteric modulations can be observed and 
may involve binding of one or two agonists or antagonists to the respective GPCR homo- or 
heteromer. In 2005, Durroux proposed mathematical models attempting to explain the complex 
allosteric interactions observed between ligand binding sites within dimeric complexes. [32]. 
4. Asymmetry at the Level of Ligand-Induced Conformation Changes 
With the exception of neutral antagonists, binding of all other types of ligands ranging from full 
inverse agonists to full agonists induce conformational changes in GPCRs. Negative and positive 
cooperativity at the level of ligand binding is further propagated to the subsequent conformational 
changes within the dimer. Such cross-conformational switches between the two protomers of GPCR 
dimers have been observed in some cases (Figure 3). In the µOR/α2A-AR heteromer, morphine binding 
to the µOR triggers an inhibitory conformational change with subsecond kinetics in the 
norepinephrine-occupied α2A-AR as monitored directly by FRET in living cells [29]. 
Figure 3. Conformational changes within a GPCR dimer. (a) Agonist A binding to the 
VFT of GB1 induces conformational changes that are transmitted to the VFT and the 
transmembrane (TM) domain of GB2 and activate its G protein. Binding of agonist A to 
the VFT of GB1 can also activate the TM domain of GB1 which then trans-activates the 
TM domain of GB2 and its G protein; (b) Binding of agonist A to μOR induces a 
conformational switch in α2A-AR resulting in negative modulation of α2A-AR-dependent 
signaling. Panel (a) has been modified from reference 32. 
 
Asymmetric ligand-induced conformational changes within GPCR dimers have been fully 
characterized in the GABAB receptor. Within this obligatory heterodimer, GB1 and GB2 subunits 
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accomplish different tasks. The role of the GB2 is to traffic GB1 to the membrane where the VFT of 
GB1 binds to GABA and trans-activates GB2, which in turn couples to Gi proteins [33]. By analyzing 
chimeric and deletion constructs of GB1 and GB2, the authors show that several different 
conformational changes are necessary for full G protein activation. GABA-induced changes in the 
relative position of the VFTs of GB1 and GB2 activate the transmembrane (TM) portion of GB2 most 
likely through two allosteric pathways: (1) one direct from the GB2 VFT to the GB2 TM portion and (2) 
a second one that interconnects the GB1 VFT to GB1 TM portion, which, in turn, trans-activates GB2 
TM portion [17,34]. 
Recently, Damian et al. monitored conformational changes within purified BLT1 receptor dimers, 
which were labeled with a single 5-hydroxytryptophan [15]. They showed that a receptor dimer with 
only a single agonist-occupied subunit can trigger G protein cis-activation. Interestingly, asymmetric 
conformational changes were observed even when both protomers were occupied by the same agonist. 
This asymmetry was highly dependent on the coupling of the dimer to purified G proteins. Altogether, 
asymmetric ligand-induced conformational changes have been monitored with several different 
techniques using different GPCRs either in living cells or as purified proteins. 
5. Asymmetry at the Level of GPCR-Interacting Proteins (GIPs) 
In addition to heterotrimeric G proteins, most GPCRs also bind to other intracellular proteins either 
directly or indirectly forming large protein complexes as exemplified by the melatonin MT1 and MT2 
receptors [35,36]. Among those proteins that directly interact with GPCRs, GPCR kinases (GRKs) and 
arrestins are probably the most studied. GPCR signaling is believed to involve the sequential 
interaction of the activated receptor with the G protein, GRKs and arrestin. In contrast to this current 
model, recent observations made with energy transfer techniques however suggest that these different 
events might be interconnected and might overlap in time [37]. Recruitment of GRK2 to the α2A-AR, 
for instance, was shown to occur before dissociation of the G protein, therefore raising the question of 
the exact molecular organization of this transient protein complex. A first hint of the putative 
organization of such a complex came from crystallographic data of the GRK2/Gαq/Gβ1γ2 complex. 
These data showed that GRK2 can bind Gβγ and Gαq subunits simultaneously while maintaining a 
surface for a possible interaction with the receptor [38]. 
Arrestin is believed to be recruited after the first wave of G protein-dependent signaling events and 
to compete with G proteins and other GIPs for receptor binding. However, recent data on the 
parathyroid hormone receptor (PTHR) suggest that at least part of the arrestin binding might be faster 
than anticipated and occur within a pre-associated complex depending on the GIP Na/H exchange 
regulatory factor-1 (NHERF1). These results raise once again the question of the composition of 
GPCR-associated complexes [39]. 
Recent advances in proteomic approaches for the identification of GPCR-associated protein 
complexes provided a number of further GIPs that directly or indirectly interact with intracellular 
domains of GPCRs [40,41]. Among these domains, the C-terminal tail and the third intracellular (i3) 
loop of the receptor have been shown to be the major interacting domains [42]. Many of these proteins 
appear to bind constitutively to receptors [43,44]. In order to better understand the exact molecular 
architecture of these complexes, their precise composition, which might be dynamically regulated in 
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space and time, needs to be determined. It is quite logical to anticipate that GPCRs are likely to bind 
simultaneously, in a constitutive or a ligand-dependent manner, several GIPs. Binding of these proteins 
to the extended surface of receptor dimers, offers many possibilities for the spatiotemporal interaction 
of several GIPs with the same receptor. Some of these interactions may depend on receptor domains 
that are sufficiently distinct to allow simultaneous binding to the receptor, others are likely to overlap. 
As illustrated above for G proteins, asymmetric binding of GIPs to GPCR dimers might be a solution 
to accommodate simultaneous binding of several GIPs (Figure 4). This has been recently illustrated in 
the ternary complex between the melatonin MT1 receptor, Gi proteins and the regulator of G protein 
signaling (RGS) 20 [44]. This study shows that Gi and RGS20 are both constitutively binding to 
overlapping, membrane-proximal domains of MT1. These data strongly imply that Gi and RGS20 bind 
to two different protomers within the homodimer. 
Figure 4. Symmetry (a) and asymmetry (b) of GIP and G protein coupling within a GPCR dimer. 
 
Similar observations were made for heteromeric complexes of MT1 with MT2, the second melatonin 
receptor, suggesting the formation of an asymmetric quaternary complex with MT1 binding to RGS20 
and MT2 binding to Gi. This example suggests that a receptor, which is not regulated by a specific GIP, 
could become sensitive to the action of this GIP when heterodimerizing with a GIP-binding receptor. This 
latter observation thus provides additional options in fine-tuning GPCR function in a context-dependent 
manner. 
6. Conclusions and Perspectives 
GPCR dimerization is a topic of great interest due to the potential importance of the functional 
consequences of such interactions on signal transduction pathways. Emerging evidence indicates 
asymmetric function of GPCR dimers and communication between the two protomers of the dimer at 
the level of ligand binding, ligand-induced conformational changes and interaction with intracellular 
signaling proteins. Negative and positive allosteric interactions between the two orthosteric binding 
sites of GPCR homo- and heterodimers may have major consequences on the pharmacology and 
functional drug outcomes. 
Although monomeric GPCRs are able to bind and activate G proteins, formation of receptor dimers 
clearly offers additional opportunities for regulating G protein activation and signal transduction by 
accommodating the simultaneous binding of other regulatory GIPs to the receptor. 
Finally, formation of higher-order oligomeric clusters needs to be considered in the future. Despite 
the existence of an extensive literature on GPCR dimerization, the precise oligomerization state of 
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GPCRs remains in most cases unknown. Atomic force microscopy studies provided convincing 
evidence that rhodopsin is organized as long oligomeric arrays of dimers in rod outer segment 
membranes [45]. This idea was further extended in molecular docking studies based on the resolved 
structures of rhodopsin and Gt by proposing an hexameric complex composed of two Gt proteins and a 
rhodopsin tetramer [46]. These modeling studies obviously warrant experimental confirmation but 
provide already an interesting framework for the organization and asymmetric binding of different 
GIPs to GPCR oligomers. Formation of oligomeric complexes might not be restricted to rhodopsin as 
formation of tetrameric complexes has been proposed for the GABAB receptors, which are composed 
of two obligatory GABAB heterodimers [47]. Finally, the putative dynamic regulation of GPCR 
oligomerization might introduce a further level of regulation for GPCR function. 
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